Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 4:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 15,126 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Randomized Controlled Study Clear all
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Healthy Males

NCT02306876
View directory record Official record
Conditions
Healthy
Interventions
PF-06412562 3mg BID, PF-06412562 15mg BID, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
3
States / cities
Arcadia, California • Glendale, California
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Oct 23, 2026, 4:14 AM EDT
Terminated Phase 3 Interventional Results available

AURORA: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH)

NCT03028740
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
Placebo, Cenicriviroc
Drug
Lead sponsor
Tobira Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,778 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
204
States / cities
Birmingham, Alabama • Cullman, Alabama • Dothan, Alabama + 144 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Oct 23, 2026, 4:14 AM EDT
Completed Phase 2 Interventional Results available

A Study Evaluating the Safety and Efficacy of Upadacitinib in Adults With Active Ankylosing Spondylitis

NCT03178487
View directory record Official record
Conditions
Ankylosing Spondylitis (AS)
Interventions
Upadacitinib, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
22
States / cities
Phoenix, Arizona • Beverly Hills, California • Covina, California + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2023 · Synced Oct 23, 2026, 4:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study to Evaluate the Iovera° Device for Temporary Relief From Knee Pain

NCT02260921
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
iovera°, Sham Comparator
Device
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
35 Years to 75 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
17
States / cities
Covina, California • Sacramento, California • Bradenton, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2024 · Synced Oct 23, 2026, 4:14 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of IV Infusion of Investigational Agent (TZP-101) in Patients With Severe Diabetic Gastroparesis

NCT00612014
View directory record Official record
Conditions
Gastroparesis, Diabetes Mellitus
Interventions
5% dextrose in water, TZP-101
Drug
Lead sponsor
Tranzyme, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
6
States / cities
San Francisco, California • Anderson, Indiana • Kansas City, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2012 · Synced Oct 23, 2026, 4:14 AM EDT
Completed Phase 2 Interventional Results available

A Study of JZP150 in Adults With Posttraumatic Stress Disorder

NCT05178316
View directory record Official record
Conditions
Post Traumatic Stress Disorder
Interventions
JZP150, Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
52
States / cities
Phoenix, Arizona • Bryant, Arkansas • Rogers, Arkansas + 45 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2024 · Synced Oct 23, 2026, 4:14 AM EDT
Terminated Phase 3 Interventional Results available

Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)

NCT01601704
View directory record Official record
Conditions
Obesity, Overweight
Interventions
NB32, PBO, Weight Management Program
Drug · Behavioral
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
45 Years and older
Enrollment
8,910 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
224
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 221 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Oct 23, 2026, 4:14 AM EDT
Not listed No phase listed Observational

Study of Paraesophageal Hernia Repair With Small Intestine Submucosa

NCT00786084
View directory record Official record
Conditions
Hiatal Hernia, Paraesophageal Hernia
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
4
States / cities
St Louis, Missouri • Portland, Oregon • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 1, 2009 · Synced Oct 23, 2026, 4:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of ERCP Mechanical Simulator (EMS) Practice on Endoscopic Retrograde Cholangiopancreatography (ERCP) Training

NCT01080833
View directory record Official record
Conditions
Training
Interventions
ERCP mechanical simulator practice
Device
Lead sponsor
East Bay Institute for Research and Education
Other
Eligibility
30 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Mar 19, 2010 · Synced Oct 23, 2026, 4:14 AM EDT
Completed Phase 2 Interventional

A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome

NCT01494233
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
250 mg LX1033 tablets, Placebo tablet
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
373 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
81
States / cities
Huntsville, Alabama • Tempe, Arizona • Tucson, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2015 · Synced Oct 23, 2026, 4:14 AM EDT
Terminated Phase 2 Interventional Results available

Pilot Trial of Resistant Starch in Stage I-III Colorectal Cancer Survivors

NCT03781778
View directory record Official record
Conditions
Colon Cancer, Rectal Cancer, Cancer Survivor, Colorectal Adenocarcinoma, Stage I Colorectal Cancer AJCC v8, Stage II Colorectal Cancer AJCC v8, Stage IIA Colorectal Cancer AJCC v8, Stage IIB Colorectal Cancer AJCC v8, Stage IIC Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8
Interventions
Dietary Intervention (resistant starch), Dietary Intervention (regular starch), Questionnaire Administration
Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 6, 2022 · Synced Oct 23, 2026, 4:14 AM EDT
Recruiting Not applicable Interventional

Testing a Web-based Intervention for Radioactive Iodine Symptom Management to Improve Health-related Quality of Life Among Differentiated Thyroid Cancer Patients

NCT06853925
View directory record Official record
Conditions
Thyroid Neoplasms
Interventions
Radioactive Iodine Support (RAI Support), Treatment as Usual (TAU)
Behavioral · Other
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Oct 23, 2026, 4:14 AM EDT
Not listed Not applicable Interventional

Dutasteride for Improving Peri-Operative and Long-Term Outcomes of Photoselective Vaporization of the Prostate (DOP)

NCT00274417
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
Interventions
dutasteride
Drug
Lead sponsor
Urology of Virginia
Other
Eligibility
50 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Norfolk, Virginia • Virginia Beach, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 18, 2007 · Synced Oct 23, 2026, 4:14 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study of Solosec® for the Treatment of Trichomoniasis

NCT03935217
View directory record Official record
Conditions
Trichomonas Infection
Interventions
Secnidazole, Placebo
Drug
Lead sponsor
Lupin Research Inc
Industry
Eligibility
12 Years and older · Female only
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
11
States / cities
Birmingham, Alabama • North Miami, Florida • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2023 · Synced Oct 23, 2026, 4:14 AM EDT
Completed Phase 3 Interventional Results available

Controlled Study of Post-transplant Azacitidine for Prevention of Acute Myelogenous Leukemia and Myelodysplastic Syndrome Relapse (VZ-AML-PI-0129)

NCT00887068
View directory record Official record
Conditions
Leukemia, AML, MDS
Interventions
Azacitidine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 14, 2020 · Synced Oct 23, 2026, 4:14 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of S-309309 in Obese Adults

NCT05925114
View directory record Official record
Conditions
Obesity
Interventions
S-309309, Placebo
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years and older
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
49
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 40 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2025 · Synced Oct 23, 2026, 4:14 AM EDT
Completed Phase 2 Interventional

A Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and mFOLFOX-6 in Participants With Previously Untreated Metastatic Colorectal Cancer

NCT01399684
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
5-Fluorouracil, Bevacizumab, Folinic acid, MEGF0444A, Oxaliplatin, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
23
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2016 · Synced Oct 23, 2026, 4:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Evaluate Formulations And Food Effect On GSK364735 In Healthy Subjects.

NCT00386347
View directory record Official record
Conditions
HIV Infection, Infection, Human Immunodeficiency Virus
Interventions
GSK364735 oral solution and oral tablets
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 4, 2012 · Synced Oct 23, 2026, 4:14 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety Study of KIACTA in Preventing Renal Function Decline in AA Amyloidosis

NCT01215747
View directory record Official record
Conditions
Amyloidosis
Interventions
KIACTA (eprodisate disodium), Placebo
Drug
Lead sponsor
C.T. Development America, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
3
States / cities
Glendale, California • Boston, Massachusetts • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 10, 2016 · Synced Oct 23, 2026, 4:14 AM EDT
Completed Phase 3 Interventional Results available

Comparison Between Podofilox Topical Gel 0.5% and Allergan's Condylox® Gel 0.5% for External Anogenital Warts

NCT03532776
View directory record Official record
Conditions
External Anogenital Warts
Interventions
Podofilox Gel 0.5%, Condylox Topical Gel 0.5%, Placebo Gel
Drug
Lead sponsor
Dermax SA
Industry
Eligibility
18 Years to 65 Years
Enrollment
466 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
4
States / cities
Miami, Florida • Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 27, 2021 · Synced Oct 23, 2026, 4:14 AM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of CC-90001 in Participants With Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis

NCT04048876
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease, Liver Cirrhosis
Interventions
CC-90001, Placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
64
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 48 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2023 · Synced Oct 23, 2026, 4:14 AM EDT
Completed Phase 2 Interventional

A Study of the Efficacy and Safety of KUS121 in Participants With Acute Non-Arteritic Central Retinal Artery Occlusion (CRAO)

NCT06178055
View directory record Official record
Conditions
Central Retinal Artery Occlusion
Interventions
KUS121 high dose, KUS121 low dose, Sham procedure
Drug
Lead sponsor
Kyoto Drug Discovery and Development Co., Ltd.
Industry
Eligibility
20 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
11
States / cities
Encino, California • Huntington Beach, California • Oakland, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 23, 2026, 4:14 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Oral Bosentan in Pulmonary Arterial Hypertension Class II

NCT00091715
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
bosentan, placebo
Drug
Lead sponsor
Actelion
Industry
Eligibility
12 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
6
States / cities
Birmingham, Alabama • Torrance, California • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2011 · Synced Oct 23, 2026, 4:14 AM EDT
Completed Phase 3 Interventional Results available

EINSTEIN Junior: Oral Rivaroxaban in Children With Venous Thrombosis

NCT02234843
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Standard of Care
Drug
Lead sponsor
Bayer
Industry
Eligibility
Up to 17 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
23
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2020 · Synced Oct 23, 2026, 4:14 AM EDT